Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp423 | Osteoporosis: treatment | ECTS2013

Three years' experience of zoledronic acid use in the treatment of postmenopausal osteoporosis

Yureneva Svetlana , Yakushevskaya Oksana , Kuznetsov Sergey , Ivanets Tatyana , Smetnik Vera , Sukchich Gennady

Introduction: We aimed to study efficacy of zoledronic acid (Zol) in the treatment of postmenopausal osteoporosis within 3 years.Methods: Clinical, bone mineral density (BMD) by DEXA (L1–L4, femoral Neck) (baseline, 12, 24, and 36 months); biochemical; immunoenzyme assay of bone turnover markers (BTM) – osteocalcin (OK) β-C-terminal telopeptides of type 1 collagen (CTX) (baseline, 1, 3, 6, 9, and 12 after one, two, three infusions).<p ...